Zepbound 10 MG/0.5 ML pen 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9DBK
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,187
Award facts
- Contract value 100% obligated
- $19,186.86 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $19,186.86 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injectors on January 13, 2026, with an ultimate completion date of January 14, 2026. This is a firm fixed-price, non-set-aside contract performed at the contractor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is a major pharmaceutical distributor serving federal healthcare systems, particularly military and veteran medical programs. The delivery order is executed under a larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical valued at $999,999,999.00 through December 2026, which enables the contractor to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare operations globally.
This procurement reflects the Department of Defense's ongoing need for specialty pharmaceutical products, including obesity and weight management medications, to support military treatment facilities and healthcare beneficiaries. Zepbound (tirzepatide) is a glucagon-like peptide-1 receptor agonist used in diabetes and weight management treatment. As a competitively awarded delivery order under the DLA's pharmaceutical prime vendor contract structure, this award demonstrates AmerisourceBergen's established capability to efficiently fulfill federal medical supply requirements. The parent company, Cencora, Inc., also holds a separate primary Indefinite Delivery Contract with DLA valued at up to $999,999,999.00 through December 2031, establishing the organization as a critical supplier within the federal pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26F9DBK?
SPE2DR26F9DBK was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26F9DBK worth?
The government has obligated $19,187 on SPE2DR26F9DBK.
Is contract SPE2DR26F9DBK an order under another contract?
Yes. SPE2DR26F9DBK is a delivery order under SPE2DR25D1017, an indefinite delivery contract.
Was contract SPE2DR26F9DBK competed?
The extent of competition for SPE2DR26F9DBK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award